Skip to main content
William Hope

Professor William Hope
FRACP, FRCPA, PhD

Publications

What type of publication do you want to show?

2024

The pathobiology of human fungal infections.

Brown, G. D., Ballou, E. R., Bates, S., Bignell, E. M., Borman, A. M., Brand, A. C., . . . Wilson, D. (2024). The pathobiology of human fungal infections.. Nature reviews. Microbiology, 22(11), 687-704. doi:10.1038/s41579-024-01062-w

DOI
10.1038/s41579-024-01062-w
Journal article

<i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparedness.

Dubey, V., Farrington, N., Harper, N., Johnson, A., Horner, I., Stevenson, A., . . . Hope, W. (2024). <i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparedness.. Antimicrobial agents and chemotherapy, 68(10), e0022224. doi:10.1128/aac.00222-24

DOI
10.1128/aac.00222-24
Journal article

Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia-a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.

Flett, L., Abdelatif, R., Baz, S. A., Brady, S., Corbacho, B., Common, K., . . . Barlow, G. (2024). Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia-a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.. Trials, 25(1), 427. doi:10.1186/s13063-024-08272-w

DOI
10.1186/s13063-024-08272-w
Journal article

Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.

Reza, N., Gerada, A., Stott, K. E., Howard, A., Sharland, M., & Hope, W. (2024). Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.. Clinical microbiology reviews, 37(2), e0013923. doi:10.1128/cmr.00139-23

DOI
10.1128/cmr.00139-23
Journal article

Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loop.

Howard, A., Reza, N., Aston, S., Woods, B., Gerada, A., Buchan, I., . . . Märtson, A. -G. (2024). Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loop.. The Lancet. Infectious diseases, 24(1), e47-e58. doi:10.1016/s1473-3099(23)00367-5

DOI
10.1016/s1473-3099(23)00367-5
Journal article

2023

Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need

Yasinskaya, Y., Bala, S., Waack, U., Dixon, C., Higgins, K., Moore, J. N., . . . Farley, J. (2023). Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need. CLINICAL INFECTIOUS DISEASES, 77(3), 380-387. doi:10.1093/cid/ciad195

DOI
10.1093/cid/ciad195
Journal article

Trichosporon inkin and Cutibacterium acnes bioprosthetic aortic valve endocarditis and prosthetic aortic root abscess with multi-focal emboli

Kempson, F., Woolley, S., Coles, Z., Kenawy, A., Muntasser, H., Ghadiri, N., . . . van Aartsen, J. J. (2023). Trichosporon inkin and Cutibacterium acnes bioprosthetic aortic valve endocarditis and prosthetic aortic root abscess with multi-focal emboli. Clinical Infection in Practice, 19, 100233. doi:10.1016/j.clinpr.2023.100233

DOI
10.1016/j.clinpr.2023.100233
Journal article

ChatGPT and antimicrobial advice: the end of the consulting infection doctor?

Howard, A., Hope, W., & Gerada, A. (2023). ChatGPT and antimicrobial advice: the end of the consulting infection doctor?. LANCET INFECTIOUS DISEASES, 23(4), 405. doi:10.1016/S1473-3099(23)00113-5

DOI
10.1016/S1473-3099(23)00113-5
Journal article

2022

Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings

Darlow, C. A., McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(12), 3349-3357. doi:10.1093/jac/dkac323

DOI
10.1093/jac/dkac323
Journal article

Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance

Darlow, C. A., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(5), 1334-1343. doi:10.1093/jac/dkac038

DOI
10.1093/jac/dkac038
Journal article

Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance

Farrington, N., McEntee, L., Johnson, A., Unsworth, J., Darlow, C., Jimenez-Valverde, A., . . . Hope, W. (2022). Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 66(4). doi:10.1128/aac.02181-21

DOI
10.1128/aac.02181-21
Journal article

2021

Optimizing antimicrobial use: challenges, advances and opportunities

Rawson, T. M., Wilson, R. C., O'Hare, D., Herrero, P., Kambugu, A., Lamorde, M., . . . Holmes, A. H. (2021). Optimizing antimicrobial use: challenges, advances and opportunities. NATURE REVIEWS MICROBIOLOGY, 19(12), 747-758. doi:10.1038/s41579-021-00578-9

DOI
10.1038/s41579-021-00578-9
Journal article

The praziquantel in preschoolers (PIP) trial: study protocol for a phase II PK/PD-driven randomised controlled trial of praziquantel in children under 4 years of age

Webb, E. L., Edielu, A., Wu, H. W., Kabatereine, N. B., Tukahebwa, E. M., Mubangizi, A., . . . Bustinduy, A. L. (2021). The praziquantel in preschoolers (PIP) trial: study protocol for a phase II PK/PD-driven randomised controlled trial of praziquantel in children under 4 years of age. TRIALS, 22(1). doi:10.1186/s13063-021-05558-1

DOI
10.1186/s13063-021-05558-1
Journal article

Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting

Sadouki, Z., McHugh, T. D., Aarnoutse, R., Canseco, J. O., Darlow, C., Hope, W., . . . Kloprogge, F. (2021). Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(9), 2252-2259. doi:10.1093/jac/dkab160

DOI
10.1093/jac/dkab160
Journal article

Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy

Gastine, S., Hope, W., Hempel, G., Petraitiene, R., Petraitis, V., Mickiene, D., . . . Groll, A. H. (2021). Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(2). doi:10.1128/AAC.01574-20

DOI
10.1128/AAC.01574-20
Journal article

Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models"

Das, S., Everett, M., Zalacain, M., & Hope, W. (2021). Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(2). doi:10.1128/AAC.02249-20

DOI
10.1128/AAC.02249-20
Journal article

2020

FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development

Byrne, J. M., Waack, U., Weinstein, E. A., Joshi, A., Shurland, S. M., Iarikov, D., . . . Farley, J. J. (2021). FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(1). doi:10.1128/AAC.01983-20

DOI
10.1128/AAC.01983-20
Journal article

Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae

Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 64(11). doi:10.1128/AAC.01076-20

DOI
10.1128/AAC.01076-20
Journal article

Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.

Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.. Antimicrob Agents Chemother, 64(11). doi:10.1128/AAC.01076-20

DOI
10.1128/AAC.01076-20
Journal article

How to design a study to evaluate therapeutic drug monitoring in infectious diseases?

Martson, A. -G., Sturkenboom, M. G. G., Stojanova, J., Cattaneo, D., Hope, W., Marriott, D., . . . Alffenaar, J. -W. C. (2020). How to design a study to evaluate therapeutic drug monitoring in infectious diseases?. Clinical Microbiology and Infection, 26(8), 1008-1016. doi:10.1016/j.cmi.2020.03.008

DOI
10.1016/j.cmi.2020.03.008
Journal article

Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review

McAleenan, A., Ambrose, P. G., Bhavnani, S. M., Drusano, G. L., Hope, W. W., Mouton, J. W., . . . MacGowan, A. P. (2020). Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(6), 1374-1389. doi:10.1093/jac/dkaa005

DOI
10.1093/jac/dkaa005
Journal article

Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>

Johnson, A., McEntee, L., Farrington, N., Kolamunnage-Dona, R., Franzoni, S., Vezzelli, A., . . . Hope, W. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(6). doi:10.1128/AAC.00180-20

DOI
10.1128/AAC.00180-20
Journal article

An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial

Hill, L. F., Turner, M. A., Lutsar, I., Heath, P. T., Hardy, P., Linsell, L., . . . Sharland, M. (2020). An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. TRIALS, 21(1). doi:10.1186/s13063-020-4184-8

DOI
10.1186/s13063-020-4184-8
Journal article

Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial

Benitez-Cano, A., Luque, S., Sorli, L., Carazo, J., Ramos, I., Campillo, N., . . . Grau, S. (2020). Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. CRITICAL CARE, 24(1). doi:10.1186/s13054-020-2763-4

DOI
10.1186/s13054-020-2763-4
Journal article

2019

Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous <i>Candida</i> Meningoencephalitis

Petraitis, V., Petraitiene, R., Valdez, J. M., Pyrgos, V., Lizak, M. J., Klaunberg, B. A., . . . Walsh, T. J. (2019). Amphotericin B Penetrates into the Central Nervous System through Focal Disruption of the Blood-Brain Barrier in Experimental Hematogenous <i>Candida</i> Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(12). doi:10.1128/AAC.01626-19

DOI
10.1128/AAC.01626-19
Journal article

Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model

Avedissian, S. N., Pais, G. M., O'Donnell, J. N., Lodise, T. P., Liu, J., Prozialeck, W. C., . . . Scheetz, M. H. (2019). Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(8), 2326-2334. doi:10.1093/jac/dkz167

DOI
10.1093/jac/dkz167
Journal article

Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i>

Cojutti, P. G., Maximova, N., Schillani, G., Hope, W., & Pea, F. (2019). Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i>. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(6), 1648-1655. doi:10.1093/jac/dkz065

DOI
10.1093/jac/dkz065
Journal article

Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans.

Bulitta, J. B., Hope, W. W., Eakin, A. E., Guina, T., Tam, V. H., Louie, A., . . . Hoover, J. L. (2019). Generating Robust and Informative Nonclinical <i>In Vitro</i> and <i>In Vivo</i> Bacterial Infection Model Efficacy Data To Support Translation to Humans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(5). doi:10.1128/AAC.02307-18

DOI
10.1128/aac.02307-18
Journal article

Population Pharmacokinetic Modeling of VL-2397, A Novel Systemic Antifungal Agent: Analysis of a Single and Multiple Ascending Dose Study in Healthy Subjects.

Kovanda, L. L., Sullivan, S. M., Smith, L. R., Desai, A. V., Bonate, P. L., & Hope, W. W. (2019). Population Pharmacokinetic Modeling of VL-2397, A Novel Systemic Antifungal Agent: Analysis of a Single and Multiple Ascending Dose Study in Healthy Subjects.. Antimicrobial agents and chemotherapy. doi:10.1128/aac.00163-19

DOI
10.1128/aac.00163-19
Journal article

Short Course High-dose Liposomal Amphotericin B for HIV-associated Cryptococcal Meningitis: A phase-II Randomized Controlled Trial.

Jarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., . . . Harrison, T. S. (2019). Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 68(3), 393-401. doi:10.1093/cid/ciy515

DOI
10.1093/cid/ciy515
Journal article

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial (vol 19, 649, 2018)

Lawrence, D. S., Youssouf, N., Molloy, S. F., Alanio, A., Alufandika, M., Boulware, D. R., . . . Jarvis, J. N. (2019). AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial (vol 19, 649, 2018). TRIALS, 20. doi:10.1186/s13063-018-3155-9

DOI
10.1186/s13063-018-3155-9
Journal article

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

Andes, D. R., Ghannoum, M. A., Mukherjee, P. K., Kovanda, L. L., Lu, Q., Jones, M. E., . . . Hope, W. W. (2019). Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(1). doi:10.1128/AAC.01634-18

DOI
10.1128/AAC.01634-18
Journal article

2018

Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis (vol 62, e02526-17, 2018)

Stott, K. E., Beardsley, J., Whalley, S., Kibengo, F. M., Nguyen, T. H. M., Nguyen, L. N. T., . . . Day, J. (2018). Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis (vol 62, e02526-17, 2018). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(12). doi:10.1128/AAC.02249-18

DOI
10.1128/AAC.02249-18
Journal article

Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis (vol 62, e00885-18, 2018)

Stott, K. E., Beardsley, J., Kolamunnage-Dona, R., Castelazo, A. S., Kibengo, F. M., Nguyen, T. H. M., . . . Hope, W. (2018). Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis (vol 62, e00885-18, 2018). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(12). doi:10.1128/AAC.02254-18

DOI
10.1128/AAC.02254-18
Journal article

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial

Lawrence, D. S., Youssouf, N., Molloy, S. L. F., Alanio, A., Alufandika, M., Boulware, D. R., . . . Jarvis, J. N. (2018). AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. TRIALS, 19. doi:10.1186/s13063-018-3026-4

DOI
10.1186/s13063-018-3026-4
Journal article

Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies

Cojutti, P. G., Candoni, A., Lazzarotto, D., Rabassi, N., Fanin, R., Hope, W., & Pea, F. (2018). Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(11), 2544-2550. doi:10.1111/bcp.13707

DOI
10.1111/bcp.13707
Journal article

Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i>

Merino-Bohorquez, V., Docobo-Perez, F., Sojo, J., Morales, I., Lupion, C., Martin, D., . . . Rodriguez-Bano, J. (2018). Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i>. CLINICAL MICROBIOLOGY AND INFECTION, 24(11), 1177-1183. doi:10.1016/j.cmi.2018.02.005

DOI
10.1016/j.cmi.2018.02.005
Journal article

Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non<i>-albicans</i> spp.

Cojutti, P. G., Lugano, M., Righi, E., Della Rocca, G., Bassetti, M., Hope, W., & Pea, F. (2018). Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non<i>-albicans</i> spp.. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 74(11), 1449-1459. doi:10.1007/s00228-018-2526-1

DOI
10.1007/s00228-018-2526-1
Journal article

Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance

Cojutti, P. G., Barbarino, C., De Monte, A., Hope, W., & Pea, F. (2018). Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 74(8), 1091-1092. doi:10.1007/s00228-018-2465-x

DOI
10.1007/s00228-018-2465-x
Journal article

Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system

Stott, K. E., & Hope, W. (2018). Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 14(8), 803-815. doi:10.1080/17425255.2018.1492551

DOI
10.1080/17425255.2018.1492551
Journal article

Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease

Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 62(4), e01909-e01917. doi:10.1128/aac.01909-17

DOI
10.1128/aac.01909-17
Journal article

Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a <i>post hoc</i> analysis of the SECURE trial

Kontoyiannis, D. P., Selleslag, D., Mullane, K., Cornely, O. A., Hope, W., Lortholary, O., . . . Patterson, T. F. (2018). Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a <i>post hoc</i> analysis of the SECURE trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(3), 757-763. doi:10.1093/jac/dkx423

DOI
10.1093/jac/dkx423
Journal article

Antifungal Dosing Considerations for Term and Preterm Infants

Lestner, J., & Hope, W. (2019). Antifungal Dosing Considerations for Term and Preterm Infants. In Infectious Disease and Pharmacology (pp. 185-191). Elsevier. doi:10.1016/b978-0-323-54391-0.00015-1

DOI
10.1016/b978-0-323-54391-0.00015-1
Chapter

2017

Pharmacodynamics of teicoplanin against MRSA

Ramos-Martin, V., Johnson, A., McEntee, L., Farrington, N., Padmore, K., Cojutti, P., . . . Hope, W. W. (2017). Pharmacodynamics of teicoplanin against MRSA. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(12), 3382-3389. doi:10.1093/jac/dkx289

DOI
10.1093/jac/dkx289
Journal article

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats

Schmitt-Hoffmann, A. -H., Kato, K., Townsend, R., Potchoiba, M. J., Hope, W. W., Andes, D., . . . Schneidkraut, M. J. (2017). Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(12). doi:10.1128/AAC.01292-17

DOI
10.1128/AAC.01292-17
Journal article

A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately?

Rawson, T. M., Moore, L. S. P., Hernandez, B., Charani, E., Castro-Sanchez, E., Herrero, P., . . . Holmes, A. H. (2017). A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately?. CLINICAL MICROBIOLOGY AND INFECTION, 23(8), 524-532. doi:10.1016/j.cmi.2017.02.028

DOI
10.1016/j.cmi.2017.02.028
Journal article

PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (SPHENISCUS DEMERSUS) AFTER SINGLE AND MULTIPLE DOSES.

Hyatt, M. W., Wiederhold, N. P., Hope, W. W., & Stott, K. E. (2017). PHARMACOKINETICS OF ORALLY ADMINISTERED VORICONAZOLE IN AFRICAN PENGUINS (<i>SPHENISCUS DEMERSUS</i>) AFTER SINGLE AND MULTIPLE DOSES. JOURNAL OF ZOO AND WILDLIFE MEDICINE, 48(2), 352-362. doi:10.1638/2016-0160R2.1

DOI
10.1638/2016-0160r2.1
Journal article

Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function

Cojutti, P. G., Ramos-Martin, V., Schiavon, I., Rossi, P., Baraldo, M., Hope, W., & Pea, F. (2017). Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(3). doi:10.1128/AAC.02134-16

DOI
10.1128/AAC.02134-16
Journal article

Haloprogin

Ramos-Martín, V., & Hope, W. (2017). Haloprogin. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2933-2935). doi:10.1201/9781315152110

DOI
10.1201/9781315152110
Chapter

Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy

Sime, F. B., Johnson, A., Whalley, S., Santoyo-Castelazo, A., Montgomery, A. B., Walters, K. A., . . . Roberts, J. A. (2017). Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01763-16

DOI
10.1128/AAC.01763-16
Journal article

2016

Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.

Ramos-Martín, V., Neely, M. N., McGowan, P., Siner, S., Padmore, K., Peak, M., . . . Hope, W. W. (2016). Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.. The Journal of antimicrobial chemotherapy, 71(11), 3168-3178. doi:10.1093/jac/dkw295

DOI
10.1093/jac/dkw295
Journal article

Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study

Blassmann, U., Roehr, A. C., Frey, O. R., Vetter-Kerkhoff, C., Thon, N., Hope, W., . . . Huge, V. (2016). Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. CRITICAL CARE, 20. doi:10.1186/s13054-016-1523-y

DOI
10.1186/s13054-016-1523-y
Journal article

Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy

Bustinduy, A. L., Waterhouse, D., de Sousa-Figueiredo, J. C., Roberts, S. A., Atuhaire, A., Van Dam, G. J., . . . Stothard, J. R. (2016). Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. mBio, 7(4). doi:10.1128/mBio.00227-16

DOI
10.1128/mBio.00227-16
Journal article

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)

Kovanda, L. L., Desai, A. V., Lu, Q., Townsend, R. W., Akhtar, S., Bonate, P., & Hope, W. W. (2016). Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(8), 4568-4576. doi:10.1128/AAC.00514-16

DOI
10.1128/AAC.00514-16
Journal article

Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

Petraitis, V., Petraitiene, R., Moradi, P. W., Strauss, G. E., Katragkou, A., Kovanda, L. L., . . . Walsh, T. J. (2016). Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(5), 2718-2726. doi:10.1128/AAC.02665-15

DOI
10.1128/AAC.02665-15
Journal article

Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy

Huurneman, L. J., Neely, M., Veringa, A., Docobo Perez, F., Ramos-Martin, V., Tissing, W. J., . . . Hope, W. (2016). Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(4), 2336-2342. doi:10.1128/AAC.03023-15

DOI
10.1128/AAC.03023-15
Journal article

Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates

Ramos-Martin, V., Johnson, A., Livermore, J., McEntee, L., Goodwin, J., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. Journal of Antimicrobial Chemotherapy, 71(4), 992-1002. doi:10.1093/jac/dkv451

DOI
10.1093/jac/dkv451
Journal article

Liposomal Amphotericin B (AmBisome<SUP>®</SUP>): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions

Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016). Liposomal Amphotericin B (AmBisome<SUP>®</SUP>): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. DRUGS, 76(4), 485-500. doi:10.1007/s40265-016-0538-7

DOI
10.1007/s40265-016-0538-7
Journal article

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., . . . Ullmann, A. J. (2016). Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet, 387(10020), 760-769. doi:10.1016/S0140-6736(15)01159-9

DOI
10.1016/S0140-6736(15)01159-9
Journal article

Antifungal Pharmacokinetics and Pharmacodynamics

Hope, W., & Andes, D. R. (2016). Antifungal Pharmacokinetics and Pharmacodynamics. In Methods in Pharmacology and Toxicology (pp. 369-383). Springer New York. doi:10.1007/978-1-4939-3323-5_15

DOI
10.1007/978-1-4939-3323-5_15
Chapter

Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis

Box, H., Livermore, J., Johnson, A., McEntee, L., Felton, T. W., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 278-287. doi:10.1128/AAC.01364-15

DOI
10.1128/AAC.01364-15
Journal article

2015

Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1

Drusano, G. L., Louie, A., MacGowan, A., & Hope, W. (2016). Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(3), 1183-1193. doi:10.1128/AAC.02177-15

DOI
10.1128/AAC.02177-15
Journal article

Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2

Drusano, G. L., Hope, W., MacGowan, A., & Louie, A. (2016). Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(3), 1194-1201. doi:10.1128/AAC.02231-15

DOI
10.1128/AAC.02231-15
Journal article

Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits

Petraitiene, R., Petraitis, V., Hope, W. W., & Walsh, T. J. (2015). Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits. CLINICAL INFECTIOUS DISEASES, 61, S643-S651. doi:10.1093/cid/civ817

DOI
10.1093/cid/civ817
Journal article

Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?

Huttner, A., Harbarth, S., Hope, W. W., Lipman, J., & Roberts, J. A. (2015). Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3178-3183. doi:10.1093/jac/dkv201

DOI
10.1093/jac/dkv201
Journal article

Clinical pharmacology of antifungal agents in pediatrics: children are not small adults

Ramos-Martin, V., O'Connor, O., & Hope, W. (2015). Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. CURRENT OPINION IN PHARMACOLOGY, 24, 128-134. doi:10.1016/j.coph.2015.08.009

DOI
10.1016/j.coph.2015.08.009
Journal article

Linezolid underexposure in a patient co-treated with venlafaxine

Cojutti, P., Crapis, M., Bassetti, M., Hope, W., & Pea, F. (2015). Linezolid underexposure in a patient co-treated with venlafaxine. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 71(10), 1285-1286. doi:10.1007/s00228-015-1922-z

DOI
10.1007/s00228-015-1922-z
Journal article

Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis

Grau, S., Luque, S., Campillo, N., Samso, E., Rodriguez, U., Garcia-Bernedo, C. A., . . . Roberts, J. A. (2015). Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2854-2861. doi:10.1093/jac/dkv173

DOI
10.1093/jac/dkv173
Journal article

Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance

Docobo-Perez, F., Drusano, G. L., Johnson, A., Goodwin, J., Whalley, S., Ramos-Martin, V., . . . Hope, W. W. (2015). Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(9), 5602-5610. doi:10.1128/AAC.00752-15

DOI
10.1128/AAC.00752-15
Journal article

AMBITION-<i>cm</i>: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial

Molefi, M., Chofle, A. A., Molloy, S. F., Kalluvya, S., Changalucha, J. M., Cainelli, F., . . . Jarvis, J. N. (2015). AMBITION-<i>cm</i>: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. TRIALS, 16. doi:10.1186/s13063-015-0799-6

DOI
10.1186/s13063-015-0799-6
Journal article

Achieving target voriconazole concentrations more accurately in children and adolescents

Neely, M., Margol, A., Fu, X., van Guilder, M., Bayard, D., Schumitzky, A., . . . Hope, W. (2015). Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrobial Agents and Chemotherapy, 59(6), 3090-3097. doi:10.1128/AAC.00032-15

DOI
10.1128/AAC.00032-15
Journal article

Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against <i>Aspergillus fumigatus</i>

Al-Nakeeb, Z., Petraitis, V., Goodwin, J., Petraitiene, R., Walsh, T. J., & Hope, W. W. (2015). Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against <i>Aspergillus fumigatus</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(5), 2735-2745. doi:10.1128/AAC.04723-14

DOI
10.1128/AAC.04723-14
Journal article

Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients

Roberts, J. A., Udy, A. A., Jarrett, P., Wallis, S. C., Hope, W. W., Sharma, R., . . . Lipman, J. (2015). Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(5), 1495-1502. doi:10.1093/jac/dku564

DOI
10.1093/jac/dku564
Journal article

Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients

Wong, G., Farkas, A., Sussman, R., Daroczi, G., Hope, W. W., Lipman, J., & Roberts, J. A. (2015). Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(3), 1411-1417. doi:10.1128/AAC.04001-14

DOI
10.1128/AAC.04001-14
Journal article

Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents

Hope, W. W., Kaibara, A., Roy, M., Arrieta, A., Azie, N., Kovanda, L. L., & Benjamin, D. K. J. (2015). Population Pharmacokinetics of Micafungin and Its Metabolites M1 and M5 in Children and Adolescents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(2), 905-913. doi:10.1128/AAC.03736-14

DOI
10.1128/AAC.03736-14
Journal article

Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development

Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Hope, W. W., & Roberts, J. A. (2015). Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 36(1), 136-153. doi:10.1055/s-0034-1398490

DOI
10.1055/s-0034-1398490
Journal article

Guidelines need controls

Raoult, D., Hope, W., & Kahlmeter, G. (2015). Guidelines need controls. CLINICAL MICROBIOLOGY AND INFECTION, 21(12), 1043-1044. doi:10.1016/j.cmi.2015.09.010

DOI
10.1016/j.cmi.2015.09.010
Journal article

2014

First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole

Zhao, W., Le Guellec, C., Benjamin, D. K. J., Hope, W. W., Bourgeois, T., Watt, K. M., . . . Jacqz-Aigrain, E. (2014). First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole. CLINICAL PHARMACOKINETICS, 53(11), 1005-1018. doi:10.1007/s40262-014-0169-7

DOI
10.1007/s40262-014-0169-7
Journal article

Population Pharmacokinetics of Teicoplanin in Children

Ramos-Martin, V., Paulus, S., Siner, S., Scott, E., Padmore, K., Newland, P., . . . Hope, W. W. (2014). Population Pharmacokinetics of Teicoplanin in Children. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(11), 6920-6927. doi:10.1128/AAC.03685-14

DOI
10.1128/AAC.03685-14
Journal article

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients

Felton, T. W., McCalman, K., Malagon, I., Isalska, B., Whalley, S., Goodwin, J., . . . Hope, W. W. (2014). Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients. Clinical Pharmacology & Therapeutics, 96(4), 438-448. doi:10.1038/clpt.2014.131

DOI
10.1038/clpt.2014.131
Journal article

Gene Expression Profiles of Human Dendritic Cells Interacting with <i>Aspergillus fumigatus</i> in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface

Morton, C. O., Fliesser, M., Dittrich, M., Mueller, T., Bauer, R., Kneitz, S., . . . Loeffler, J. (2014). Gene Expression Profiles of Human Dendritic Cells Interacting with <i>Aspergillus fumigatus</i> in a Bilayer Model of the Alveolar Epithelium/Endothelium Interface. PLOS ONE, 9(5). doi:10.1371/journal.pone.0098279

DOI
10.1371/journal.pone.0098279
Journal article

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014). Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(5), 1162-1176. doi:10.1093/jac/dkt508

DOI
10.1093/jac/dkt508
Journal article

An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i>: The role of azole resistance

Gomez-Lopez, A., Forastiero, A., Cendejas-Bueno, E., Gregson, L., Mellado, E., Howard, S. J., . . . Cuenca-Estrella, M. (2014). An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i>: The role of azole resistance. MEDICAL MYCOLOGY, 52(3), 311-319. doi:10.1093/mmy/myt022

DOI
10.1093/mmy/myt022
Journal article

Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units

Aliaga, S., Clark, R. H., Laughon, M., Walsh, T. J., Hope, W. W., Benjamin, D. K., . . . Smith, P. B. (2014). Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units. PEDIATRICS, 133(2), 236-242. doi:10.1542/peds.2013-0671

DOI
10.1542/peds.2013-0671
Journal article

Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days

Livermore, J., Howard, S. J., Sharp, A. D., Goodwin, J., Gregson, L., Felton, T., . . . Hope, W. (2014). Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days. mBio, 5(1). doi:10.1128/mBio.00725-13

DOI
10.1128/mBio.00725-13
Journal article

Tissue Penetration of Antifungal Agents

Felton, T., Troke, P. F., & Hope, W. W. (2014). Tissue Penetration of Antifungal Agents. CLINICAL MICROBIOLOGY REVIEWS, 27(1), 68-88. doi:10.1128/CMR.00046-13

DOI
10.1128/CMR.00046-13
Journal article

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi

Chowdhary, A., Meis, J. F., Guarro, J., de Hoog, G. S., Kathuria, S., Arendrup, M. C., . . . Cuenca-Estrella, M. (2014). ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. CLINICAL MICROBIOLOGY AND INFECTION, 20, 47-75. doi:10.1111/1469-0691.12515

DOI
10.1111/1469-0691.12515
Journal article

ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

Tortorano, A. M., Richardson, M., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., . . . Lass-Floerl, C. (2014). ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. CLINICAL MICROBIOLOGY AND INFECTION, 20, 27-46. doi:10.1111/1469-0691.12465

DOI
10.1111/1469-0691.12465
Journal article

ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of mucormycosis 2013

Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., . . . Petrikkos, G. (2014). ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of mucormycosis 2013. CLINICAL MICROBIOLOGY AND INFECTION, 20, 5-26. doi:10.1111/1469-0691.12371

DOI
10.1111/1469-0691.12371
Journal article

ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of rare invasive yeast infections

Arendrup, M. C., Boekhout, T., Akova, M., Meis, J. F., Cornely, O. A., & Lortholary, O. (2014). ESCMID<SUP>†</SUP> and ECMM<SUP>‡</SUP> joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. CLINICAL MICROBIOLOGY AND INFECTION, 20, 76-98. doi:10.1111/1469-0691.12360

DOI
10.1111/1469-0691.12360
Journal article

EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole

Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. W. (2014). EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole. MYCOSES, 57(6), 377-379. doi:10.1111/myc.12170

DOI
10.1111/myc.12170
Journal article

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation

Groll, A. H., Castagnola, E., Cesaro, S., Dalle, J. -H., Engelhard, D., Hope, W., . . . Lehrnbecher, T. (2014). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. LANCET ONCOLOGY, 15(8), E327-E340. doi:10.1016/S1470-2045(14)70017-8

DOI
10.1016/S1470-2045(14)70017-8
Journal article

How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?

Felton, T. W., Hope, W. W., & Roberts, J. A. (2014). How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 79(4), 441-447. doi:10.1016/j.diagmicrobio.2014.04.007

DOI
10.1016/j.diagmicrobio.2014.04.007
Journal article

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., . . . Kuti, J. L. (2014). Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. LANCET INFECTIOUS DISEASES, 14(6), 498-509. doi:10.1016/S1473-3099(14)70036-2

DOI
10.1016/S1473-3099(14)70036-2
Journal article

Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy

Felton, T. W., Roberts, J. A., Lodise, T. P., Van Guilder, M., Boselli, E., Neely, M. N., & Hope, W. W. (2014). Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(7), 4094-4102. doi:10.1128/AAC.02664-14

DOI
10.1128/AAC.02664-14
Journal article

2013

Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i>

Felton, T. W., Goodwin, J., O'Connor, L., Sharp, A., Gregson, L., Livermore, J., . . . Hope, W. W. (2013). Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 5811-5819. doi:10.1128/AAC.00867-13

DOI
10.1128/AAC.00867-13
Journal article

<i>In Vitro</i> Susceptibility of <i>Aspergillus fumigatus</i> to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole

Gregson, L., Goodwin, J., Johnson, A., McEntee, L., Moore, C. B., Richardson, M., . . . Howard, S. J. (2013). <i>In Vitro</i> Susceptibility of <i>Aspergillus fumigatus</i> to Isavuconazole: Correlation with Itraconazole, Voriconazole, and Posaconazole. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5778-5780. doi:10.1128/AAC.01141-13

DOI
10.1128/AAC.01141-13
Journal article

Invasive fungal infections

Hope, W., Natarajan, P., & Goodwin, L. (2013). Invasive fungal infections. CLINICAL MEDICINE, 13(5), 507-510. doi:10.7861/clinmedicine.13-5-507

DOI
10.7861/clinmedicine.13-5-507
Journal article

Opinion: The Pharmacometrics of Infectious Disease

Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacometrics &amp; Systems Pharmacology, 2(8), 1-3. doi:10.1038/psp.2013.46

DOI
10.1038/psp.2013.46
Journal article

Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients

O'Connor, L., Livermore, J., Sharp, A. D., Goodwin, J., Gregson, L., Howard, S. J., . . . Hope, W. W. (2013). Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients. JOURNAL OF INFECTIOUS DISEASES, 208(2), 351-361. doi:10.1093/infdis/jit164

DOI
10.1093/infdis/jit164
Journal article

Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

Lestner, J., & Hope, W. W. (2013). Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 9(7), 911-926. doi:10.1517/17425255.2013.794785

DOI
10.1517/17425255.2013.794785
Journal article

Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective

Lestner, J. M., Smith, P. B., Cohen-Wolkowiez, M., Benjamin, D. K. J., & Hope, W. W. (2013). Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 75(6), 1381-1395. doi:10.1111/bcp.12025

DOI
10.1111/bcp.12025
Journal article

Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints

Sudan, A., Livermore, J., Howard, S. J., Al-Nakeeb, Z., Sharp, A., Goodwin, J., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(6), 2793-2800. doi:10.1128/AAC.00216-13

DOI
10.1128/AAC.00216-13
Journal article

Software for Dosage Individualization of Voriconazole for Immunocompromised Patients

Hope, W. W., VanGuilder, M., Donnelly, J. P., Blijlevens, N. M. A., Bruggemann, R. J. M., Jelliffe, R. W., & Neely, M. N. (2013). Software for Dosage Individualization of Voriconazole for Immunocompromised Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(4), 1888-1894. doi:10.1128/AAC.02025-12

DOI
10.1128/AAC.02025-12
Journal article

Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp.

Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. W. (2013). Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against <i>Candida</i> spp. and triazoles against <i>Aspergillus</i> spp.. DRUG RESISTANCE UPDATES, 16(6), 81-95. doi:10.1016/j.drup.2014.01.001

DOI
10.1016/j.drup.2014.01.001
Journal article

EUCAST Technical Note on Voriconazole and Aspergillus spp.

Hope, W. W., Cuenca-Estrella, M., Lass-Floerl, C., & Arendrup, M. C. (2013). EUCAST Technical Note on Voriconazole and Aspergillus spp.. CLINICAL MICROBIOLOGY AND INFECTION, 19(6), E278-E280. doi:10.1111/1469-0691.12148

DOI
10.1111/1469-0691.12148
Journal article

Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental <i>Candida</i> Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection

Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental <i>Candida</i> Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(1), 281-288. doi:10.1128/AAC.01387-12

DOI
10.1128/AAC.01387-12
Journal article

The pharmacometrics of infectious diseases

Davies, G. R., Khoo, S. H., & Hope, W. (2013). The pharmacometrics of infectious diseases. CPT: Pharmacometrics and systems pharmacology, 2, e70. Retrieved from cpt:%20pharmacomet.%20syst.%20pharmacol.%202:%20e70;%20doi:10.1038/psp.2013.46

Journal article

2012

Optimizing Micafungin Dosing in Children

Zhao, W., Hope, W. W., Manzoni, P., & Jacqz-Aigrain, E. (2012). Optimizing Micafungin Dosing in Children. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 31(11), 1211-1212. doi:10.1097/INF.0b013e3182624bac

DOI
10.1097/INF.0b013e3182624bac
Journal article

Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant <i>Aspergillus fumigatus</i> in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis

Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Warn, P. A., & Hope, W. W. (2012). Combination of Voriconazole and Anidulafungin for Treatment of Triazole-Resistant <i>Aspergillus fumigatus</i> in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(10), 5180-5185. doi:10.1128/AAC.01111-12

DOI
10.1128/AAC.01111-12
Journal article

Isolation of <i>Aspergillus</i> species from the airway of lung transplant recipients is associated with excess mortality

Felton, T. W., Roberts, S. A., Isalska, B., Brennan, S., Philips, A., Whiteside, S., . . . Hope, W. W. (2012). Isolation of <i>Aspergillus</i> species from the airway of lung transplant recipients is associated with excess mortality. JOURNAL OF INFECTION, 65(4), 350-356. doi:10.1016/j.jinf.2012.07.008

DOI
10.1016/j.jinf.2012.07.008
Journal article

Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens

Hope, W. W., Goodwin, J., Felton, T. W., Ellis, M., & Stevens, D. A. (2012). Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(10), 5303-5308. doi:10.1128/AAC.00933-12

DOI
10.1128/AAC.00933-12
Journal article

Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology (vol 50, pg 2509, 2012)

Alastruey-Izquierdo, A., Gomez-Lopez, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., . . . Cuenca-Estrella, M. (2012). Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology (vol 50, pg 2509, 2012). JOURNAL OF CLINICAL MICROBIOLOGY, 50(9), 3149. doi:10.1128/JCM.01843-12

DOI
10.1128/JCM.01843-12
Journal article

Pharmacodynamics of Itraconazole against <i>Aspergillus fumigatus</i> in an <i>In</i> <i>Vitro</i> Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration

Al-Nakeeb, Z., Sudan, A., Jeans, A. R., Gregson, L., Goodwin, J., Warn, P. A., . . . Hope, W. W. (2012). Pharmacodynamics of Itraconazole against <i>Aspergillus fumigatus</i> in an <i>In</i> <i>Vitro</i> Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(8), 4146-4153. doi:10.1128/AAC.00141-12

DOI
10.1128/AAC.00141-12
Journal article

Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints

Jeans, A. R., Howard, S. J., Al-Nakeeb, Z., Goodwin, J., Gregson, L., Majithiya, J. B., . . . Hope, W. W. (2012). Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints. JOURNAL OF INFECTIOUS DISEASES, 206(3), 442-452. doi:10.1093/infdis/jis372

DOI
10.1093/infdis/jis372
Journal article

Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections

Felton, T. W., Hope, W. W., Lomaestro, B. M., Butterfield, J. M., Kwa, A. L., Drusano, G. L., & Lodise, T. P. (2012). Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(8), 4087-4094. doi:10.1128/AAC.00521-12

DOI
10.1128/AAC.00521-12
Journal article

Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.

Alastruey-Izquierdo, A., Gómez-López, A., Arendrup, M. C., Lass-Florl, C., Hope, W. W., Perlin, D. S., . . . Cuenca-Estrella, M. (2012). Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.. Journal of clinical microbiology, 50(7), 2509-2512. doi:10.1128/jcm.00791-12

DOI
10.1128/jcm.00791-12
Journal article

Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections

Livermore, J., & Hope, W. (2012). Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 8(6), 759-765. doi:10.1517/17425255.2012.683859

DOI
10.1517/17425255.2012.683859
Journal article

Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against <i>Candida glabrata</i> Isolates with and without <i>FKS</i> Resistance Mutations

Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012). Differential <i>In Vivo</i> Activities of Anidulafungin, Caspofungin, and Micafungin against <i>Candida glabrata</i> Isolates with and without <i>FKS</i> Resistance Mutations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(5), 2435-2442. doi:10.1128/AAC.06369-11

DOI
10.1128/AAC.06369-11
Journal article

Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions

Hope, W. W., Howard, S. J., & Felton, T. W. (2012). Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. MYCOSES, 55, 33-38. doi:10.1111/j.1439-0507.2011.02114.x

DOI
10.1111/j.1439-0507.2011.02114.x
Journal article

Posaconazole: The Case for Therapeutic Drug Monitoring

Howard, S. J., Felton, T. W., Gomez-Lopez, A., & Hope, W. W. (2012). Posaconazole: The Case for Therapeutic Drug Monitoring. THERAPEUTIC DRUG MONITORING, 34(1), 72-76. doi:10.1097/FTD.0b013e31823cdeac

DOI
10.1097/FTD.0b013e31823cdeac
Journal article

Anidulafungin for Neonatal Hematogenous <i>Candida</i> Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach

Warn, P. A., Livermore, J., Howard, S., Felton, T. W., Sharp, A., Gregson, L., . . . Hope, W. W. (2012). Anidulafungin for Neonatal Hematogenous <i>Candida</i> Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 708-714. doi:10.1128/AAC.05826-11

DOI
10.1128/AAC.05826-11
Journal article

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., . . . Cuenca-Estrella, M. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). CLINICAL MICROBIOLOGY AND INFECTION, 18, 53-67. doi:10.1111/1469-0691.12041

DOI
10.1111/1469-0691.12041
Journal article

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases

Ullmann, A. J., Cornely, O. A., Donnelly, J. P., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., . . . Cuenca-Estrella, M. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. CLINICAL MICROBIOLOGY AND INFECTION, 18, 1-8. doi:10.1111/1469-0691.12037

DOI
10.1111/1469-0691.12037
Journal article

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures

Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. CLINICAL MICROBIOLOGY AND INFECTION, 18, 9-18. doi:10.1111/1469-0691.12038

DOI
10.1111/1469-0691.12038
Journal article

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. CLINICAL MICROBIOLOGY AND INFECTION, 18, 19-37. doi:10.1111/1469-0691.12039

DOI
10.1111/1469-0691.12039
Journal article

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS

Lortholary, O., Petrikkos, G., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. CLINICAL MICROBIOLOGY AND INFECTION, 18, 68-77. doi:10.1111/1469-0691.12042

DOI
10.1111/1469-0691.12042
Journal article

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., . . . Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. CLINICAL MICROBIOLOGY AND INFECTION, 18, 38-52. doi:10.1111/1469-0691.12040

DOI
10.1111/1469-0691.12040
Journal article

EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole

Arendrup, M. C., Cuenca-Estrella, M., Lass-Floel, C., & Hope, W. W. (2012). EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole. CLINICAL MICROBIOLOGY AND INFECTION, 18(7), E248-E250. doi:10.1111/j.1469-0691.2012.03890.x

DOI
10.1111/j.1469-0691.2012.03890.x
Journal article

EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)

Arendrup, M. C., Cuenca-Estrella, M., Lass-Floerl, C., & Hope, W. (2012). EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). CLINICAL MICROBIOLOGY AND INFECTION, 18(7), E246-E247. doi:10.1111/j.1469-0691.2012.03880.x

DOI
10.1111/j.1469-0691.2012.03880.x
Journal article

In vitro model of invasive pulmonary aspergillosis in the human alveolus.

Gregson, L., Hope, W. W., & Howard, S. J. (2012). In vitro model of invasive pulmonary aspergillosis in the human alveolus.. Methods in molecular biology (Clifton, N.J.), 845, 361-367. doi:10.1007/978-1-61779-539-8_24

DOI
10.1007/978-1-61779-539-8_24
Journal article

Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection.

Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2012). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection.. Antimicrob Agents Chemother..

Journal article

Population Pharmacokinetics of Voriconazole in Adults

Hope, W. W. (2012). Population Pharmacokinetics of Voriconazole in Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(1), 526-531. doi:10.1128/AAC.00702-11

DOI
10.1128/AAC.00702-11
Journal article

2011

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (vol 55, pg 4782, 2011)

Troke, P. F., Hockey, H. P., & Hope, W. W. (2011). Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients (vol 55, pg 4782, 2011). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(11), 5415. doi:10.1128/AAC.05771-11

DOI
10.1128/AAC.05771-11
Journal article

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

Troke, P. F., Hockey, H. P., & Hope, W. W. (2011). Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4782-4788. doi:10.1128/AAC.01083-10

DOI
10.1128/AAC.01083-10
Journal article

Pharmacodynamics of Echinocandins against <i>Candida glabrata</i>: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts

Howard, S. J., Livermore, J., Sharp, A., Goodwin, J., Gregson, L., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Pharmacodynamics of Echinocandins against <i>Candida glabrata</i>: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4880-4887. doi:10.1128/AAC.00621-11

DOI
10.1128/AAC.00621-11
Journal article

Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?

Rodriguez-Tudela, J. L., Hope, W., Cuenca-Estrella, M., Donnelly, J. P., Lass-Flörl, C., & Arendrup, M. C. (2011). Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?. Current Fungal Infection Reports, 5(3), 128-134. doi:10.1007/s12281-011-0058-6

DOI
10.1007/s12281-011-0058-6
Journal article

Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin

Slater, J. L., Howard, S. J., Sharp, A., Goodwin, J., Gregson, L. M., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(7), 3075-3083. doi:10.1128/AAC.01686-10

DOI
10.1128/AAC.01686-10
Journal article

Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy

Howard, S. J., Lestner, J. M., Sharp, A., Gregson, L., Goodwin, J., Slater, J., . . . Hope, W. W. (2011). Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. JOURNAL OF INFECTIOUS DISEASES, 203(9), 1324-1332. doi:10.1093/infdis/jir023

DOI
10.1093/infdis/jir023
Journal article

Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates

Cohen-Wolkowiez, M., Benjamin, D. K. J., Piper, L., Cheifetz, I. M., Moran, C., Liu, P., . . . Smith, P. B. (2011). Safety and Pharmacokinetics of Multiple-Dose Anidulafungin in Infants and Neonates. CLINICAL PHARMACOLOGY & THERAPEUTICS, 89(5), 702-707. doi:10.1038/clpt.2011.26

DOI
10.1038/clpt.2011.26
Journal article

EUCAST Technical note on Amphotericin B

Lass-Floerl, C., Arendrup, M. C., Rodriguez-Tudela, J. -L., Cuenca-Estrella, M., Donnelly, P., & Hope, W. (2011). EUCAST Technical note on Amphotericin B. CLINICAL MICROBIOLOGY AND INFECTION, 17(12), E27-E29. doi:10.1111/j.1469-0691.2011.03644.x

DOI
10.1111/j.1469-0691.2011.03644.x
Journal article

EUCAST technical note on anidulafungin

Arendrup, M. C., Rodriguez-Tudela, J. -L., Lass-Floerl, C., Cuenca-Estrella, M., Donnelly, J. P., & Hope, W. (2011). EUCAST technical note on anidulafungin. CLINICAL MICROBIOLOGY AND INFECTION, 17(11), E18-E20. doi:10.1111/j.1469-0691.2011.03647.x

DOI
10.1111/j.1469-0691.2011.03647.x
Journal article

EUCAST technical note on posaconazole

Arendrup, M. C., Cuenca-Estrella, M., Donnelly, J. P., Hope, W., Lass-Floerl, C., & Rodriguez-Tudela, J. -L. (2011). EUCAST technical note on posaconazole. CLINICAL MICROBIOLOGY AND INFECTION, 17(11), E16-E17. doi:10.1111/j.1469-0691.2011.03646.x

DOI
10.1111/j.1469-0691.2011.03646.x
Journal article

Fluconazole Loading Dose Pharmacokinetics and Safety in Infants

Piper, L., Smith, P. B., Hornik, C. P., Cheifetz, I. M., Barrett, J. S., Moorthy, G., . . . Benjamin, D. K. J. (2011). Fluconazole Loading Dose Pharmacokinetics and Safety in Infants. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 30(5), 375-378. doi:10.1097/INF.0b013e318202cbb3

DOI
10.1097/INF.0b013e318202cbb3
Journal article

Innate immunity in human newborn infants: prematurity means more than immaturity.

Strunk, T., Currie, A., Richmond, P., Simmer, K., & Burgner, D. (2011). Innate immunity in human newborn infants: prematurity means more than immaturity.. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 24(1), 25-31. doi:10.3109/14767058.2010.482605

DOI
10.3109/14767058.2010.482605
Journal article

Optimizing management of invasive mould diseases

Agrawal, S., Hope, W., Sinko, J., & Kibbler, C. (2011). Optimizing management of invasive mould diseases. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66, i45-i53. doi:10.1093/jac/dkq441

DOI
10.1093/jac/dkq441
Journal article

Robotic suturing on the FLS model possesses construct validity, is less physically demanding, and is favored by more surgeons compared with laparoscopy.

Stefanidis, D., Hope, W. W., & Scott, D. J. (2011). Robotic suturing on the FLS model possesses construct validity, is less physically demanding, and is favored by more surgeons compared with laparoscopy.. Surgical endoscopy, 25(7), 2141-2146. doi:10.1007/s00464-010-1512-1

DOI
10.1007/s00464-010-1512-1
Journal article

The management of <i>Candida</i> infections in preterm neonates and the role of micafungin

Manzoni, P., Benjamin, D. K., Hope, W., Rizzollo, S., Del Sordo, P., Stronati, M., . . . Farina, D. (2011). The management of <i>Candida</i> infections in preterm neonates and the role of micafungin. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 24, 25-28. doi:10.3109/14767058.2011.604929

DOI
10.3109/14767058.2011.604929
Journal article

2010

Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis

Felton, T. W., Baxter, C., Moore, C. B., Roberts, S. A., Hope, W. W., & Denning, D. W. (2010). Efficacy and Safety of Posaconazole for Chronic Pulmonary Aspergillosis. CLINICAL INFECTIOUS DISEASES, 51(12), 1383-1391. doi:10.1086/657306

DOI
10.1086/657306
Journal article

The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-D-Glucan, and Consequences of Delayed Antifungal Therapy

Hope, W. W., Petraitis, V., Petraitiene, R., Aghamolla, T., Bacher, J., & Walsh, T. J. (2010). The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1→3)-β-D-Glucan, and Consequences of Delayed Antifungal Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(11), 4879-4886. doi:10.1128/AAC.00673-10

DOI
10.1128/AAC.00673-10
Journal article

Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis

Lestner, J. M., Howard, S. J., Goodwin, J., Gregson, L., Majithiya, J., Walsh, T. J., . . . Hope, W. W. (2010). Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3432-3441. doi:10.1128/AAC.01586-09

DOI
10.1128/AAC.01586-09
Journal article

Population Pharmacokinetics of Micafungin in Neonates and Young Infants

Hope, W. W., Smith, P. B., Arrieta, A., Buell, D. N., Roy, M., Kaibara, A., . . . Benjamin, D. K. J. (2010). Population Pharmacokinetics of Micafungin in Neonates and Young Infants. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(6), 2633-2637. doi:10.1128/AAC.01679-09

DOI
10.1128/AAC.01679-09
Journal article

Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?

Roberts, J. A., Hope, W. W., & Lipman, J. (2010). Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 35(5), 419-420. doi:10.1016/j.ijantimicag.2010.01.022

DOI
10.1016/j.ijantimicag.2010.01.022
Journal article

Therapy for fungal diseases: opportunities and priorities

Denning, D. W., & Hope, W. W. (2010). Therapy for fungal diseases: opportunities and priorities. TRENDS IN MICROBIOLOGY, 18(5), 195-204. doi:10.1016/j.tim.2010.02.004

DOI
10.1016/j.tim.2010.02.004
Journal article

Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis

Howard, S. J., & Hope, W. W. (2010). Antifungal Therapeutic Drug Monitoring for Invasive Aspergillosis. In ASPERGILLOSIS: FROM DIAGNOSIS TO PREVENTION (pp. 217-228). doi:10.1007/978-90-481-2408-4_14

DOI
10.1007/978-90-481-2408-4_14
Chapter

Echinocandins

Perlin, D. S., & Hope, W. W. (2010). Echinocandins. In ASPERGILLOSIS: FROM DIAGNOSIS TO PREVENTION (pp. 263-279). doi:10.1007/978-90-481-2408-4_16

DOI
10.1007/978-90-481-2408-4_16
Chapter

Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants

Benjamin, D. K. J., Smith, P. B., Arrieta, A., Castro, L., Sanchez, P. J., Kaufman, D., . . . Walsh, T. J. (2010). Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants. CLINICAL PHARMACOLOGY & THERAPEUTICS, 87(1), 93-99. doi:10.1038/clpt.2009.200

DOI
10.1038/clpt.2009.200
Journal article

2009

Aspergillus

Malcolm, D., Richardson, K. B., & Hope, W. (2009). Aspergillus. In Clinical Mycology (pp. 271-296). Elsevier. doi:10.1016/b978-1-4160-5680-5.00011-6

DOI
10.1016/b978-1-4160-5680-5.00011-6
Chapter

Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring

Lestner, J. M., Roberts, S. A., Moore, C. B., Howard, S. J., Denning, D. W., & Hope, W. W. (2009). Toxicodynamics of Itraconazole: Implications for Therapeutic Drug Monitoring. CLINICAL INFECTIOUS DISEASES, 49(6), 928-930. doi:10.1086/605499

DOI
10.1086/605499
Journal article

Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis

Hope, W. W. (2009). Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis. MEDICAL MYCOLOGY, 47, S291-S298. doi:10.1080/13693780802510232

DOI
10.1080/13693780802510232
Journal article

Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect

Warn, P. A., Sharp, A., Parmar, A., Majithiya, J., Denning, D. W., & Hope, W. W. (2009). Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(8), 3453-3461. doi:10.1128/AAC.01601-08

DOI
10.1128/AAC.01601-08
Journal article

<i>Rational Testing</i> Assessing candiduria in a critically ill patient

Hope, W. W. (2009). <i>Rational Testing</i> Assessing candiduria in a critically ill patient. BRITISH MEDICAL JOURNAL, 338. doi:10.1136/bmj.b2289

DOI
10.1136/bmj.b2289
Journal article

Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis

Petraitis, V., Petraitiene, R., Hope, W. W., Meletiadis, J., Mickiene, D., Hughes, J. E., . . . Walsh, T. J. (2009). Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 53(6), 2382-2391. doi:10.1128/AAC.00329-09

DOI
10.1128/AAC.00329-09
Journal article

Aspergillus

Malcolm, D., Richardson, K. B., & Hope, W. (2009). Aspergillus. In Clinical Mycology with CD-ROM (pp. 271-296). doi:10.1016/B978-1-4160-5680-5/00011-6

DOI
10.1016/B978-1-4160-5680-5/00011-6
Chapter

Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside

Hope, W. W., & Drusano, G. L. (2009). Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. CLINICAL MICROBIOLOGY AND INFECTION, 15(7), 602-612. doi:10.1111/j.1469-0691.2009.02913.x

DOI
10.1111/j.1469-0691.2009.02913.x
Journal article

Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates

Smith, P. B., Walsh, T. J., Hope, W., Arrieta, A., Takada, A., Kovanda, L. L., . . . Benjamin, D. K. J. (2009). Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 28(5), 412-415. doi:10.1097/INF.0b013e3181910e2d

DOI
10.1097/INF.0b013e3181910e2d
Journal article

2008

Therapeutic drug monitoring for triazoles

Hope, W. W., Billaud, E. M., Lestner, J., & Denning, D. W. (2008). Therapeutic drug monitoring for triazoles. CURRENT OPINION IN INFECTIOUS DISEASES, 21(6), 580-586. doi:10.1097/QCO.0b013e3283184611

DOI
10.1097/QCO.0b013e3283184611
Journal article

Cerebrospinal Fluid and Plasma (1→3)-β-D-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous <i>Candida</i> Meningoencephalitis

Petraitiene, R., Petraitis, V., Hope, W. W., Mickiene, D., Kelaher, A. M., Murray, H. A., . . . Walsh, T. J. (2008). Cerebrospinal Fluid and Plasma (1→3)-β-D-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous <i>Candida</i> Meningoencephalitis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 52(11), 4121-4129. doi:10.1128/AAC.00674-08

DOI
10.1128/AAC.00674-08
Journal article

Interactions of <i>Aspergillus</i> with the Mucosa

Hope, W. W., & Filler, S. G. (n.d.). Interactions of <i>Aspergillus</i> with the Mucosa. In <i>Aspergillus fumigatus</i> and Aspergillosis (pp. 239-245). ASM Press. doi:10.1128/9781555815523.ch19

DOI
10.1128/9781555815523.ch19
Chapter

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., . . . Bennett, J. E. (2008). Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. CLINICAL INFECTIOUS DISEASES, 46(12), 1813-1821. doi:10.1086/588660

DOI
10.1086/588660
Journal article

Experimental Design Considerations in Pharmacokinetic Studies

Hope, W. W., Petraitis, V., & Walsh, T. J. (2008). Experimental Design Considerations in Pharmacokinetic Studies. In Unknown Book (pp. 1059-1068). Wiley. doi:10.1002/9780470249031.ch31

DOI
10.1002/9780470249031.ch31
Chapter

The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous <i>Candida</i> meningoencephalitis:: Implications for echinocandin therapy in neonates

Hope, W. W., Mickiene, D., Petraitis, V., Petraitiene, R., Kelaher, A. M., Hughes, J. E., . . . Walsh, T. J. (2008). The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous <i>Candida</i> meningoencephalitis:: Implications for echinocandin therapy in neonates. JOURNAL OF INFECTIOUS DISEASES, 197(1), 163-171. doi:10.1086/524063

DOI
10.1086/524063
Journal article

2007

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing

Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., . . . Drusano, G. L. (2007). Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(10), 3760-3762. doi:10.1128/AAC.00488-07

DOI
10.1128/AAC.00488-07
Journal article

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing

Hope, W. W., Seibel, N. L., Schwartz, C. L., Arrieta, A., Flynn, P., Shad, A., . . . Walsh, T. J. (2007). Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(10), 3714-3719. doi:10.1128/AAC.00398-07

DOI
10.1128/AAC.00398-07
Journal article

The pharmacology and clinical use of caspofungin

Hope, W. W., Shoham, S., & Walsh, T. J. (2007). The pharmacology and clinical use of caspofungin. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 3(2), 263-274. doi:10.1517/17425255.3.2.263

DOI
10.1517/17425255.3.2.263
Journal article

Pathogenesis of <i>Aspergillus fumigatus</i> and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis:: Implications for antifungal therapy

Hope, W. W., Kruhlak, M. J., Lyman, C. A., Petraitiene, R., Petraitis, V., Francesconi, A., . . . Walsh, T. J. (2007). Pathogenesis of <i>Aspergillus fumigatus</i> and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis:: Implications for antifungal therapy. JOURNAL OF INFECTIOUS DISEASES, 195(3), 455-466. doi:10.1086/510535

DOI
10.1086/510535
Journal article

Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis

Hope, W. W., Drusano, G. L., Moore, C. B., Sharp, A., Louie, A., Walsh, T. J., . . . Warn, P. A. (2007). Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 51(1), 285-295. doi:10.1128/AAC.00601-06

DOI
10.1128/AAC.00601-06
Journal article

Galactomannan antigen detection in the diagnosis of invasive aspergillosis

Verdaguer, V., Walsh, T. J., Hope, W., & Cortez, K. J. (2007). Galactomannan antigen detection in the diagnosis of invasive aspergillosis. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 7(1), 21-32. doi:10.1586/14737159.7.1.21

DOI
10.1586/14737159.7.1.21
Journal article

2006

Derivation of an in vivo drug exposure breakpoint for flucytosine against <i>Candida albicans</i> and impact of the MIC, growth rate, and resistance genotype on the antifungal effect

Hope, W. W., Warn, P. A., Sharp, A., Howard, S., Kasai, M., Louie, A., . . . Denning, D. W. (2006). Derivation of an in vivo drug exposure breakpoint for flucytosine against <i>Candida albicans</i> and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(11), 3680-3688. doi:10.1128/AAC.00369-06

DOI
10.1128/AAC.00369-06
Journal article

Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt

Anaissie, E. J., Segal, B. H., Graybill, J. R., Arndt, C., Perfect, J. R., Kleinberg, M., . . . Zaoutis, T. (2006). Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt. CLINICAL INFECTIOUS DISEASES, 43(8), 1031-1039. doi:10.1086/509116

DOI
10.1086/509116
Journal article

Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of <i>Aspergillus fumigatus</i> in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis

Francesconi, A., Kasai, M., Petraitiene, R., Petraitis, V., Kelaher, A. M., Schaufele, R., . . . Walsh, T. J. (2006). Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of <i>Aspergillus fumigatus</i> in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. JOURNAL OF CLINICAL MICROBIOLOGY, 44(7), 2475-2480. doi:10.1128/JCM.02693-05

DOI
10.1128/JCM.02693-05
Journal article

2005

Laboratory diagnosis of invasive aspergillosis

Hope, W. W., Walsh, T. J., & Denning, D. W. (2005). Laboratory diagnosis of invasive aspergillosis. LANCET INFECTIOUS DISEASES, 5(10), 609-622. doi:10.1016/S1473-3099(05)70238-3

DOI
10.1016/S1473-3099(05)70238-3
Journal article

Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis

Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., . . . Drusano, G. L. (2005). Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. JOURNAL OF INFECTIOUS DISEASES, 192(4), 673-680. doi:10.1086/432069

DOI
10.1086/432069
Journal article

The invasive and saprophytic syndromes due to <i>Aspergillus</i> spp.

Hope, W. W., Walsh, T. J., & Denning, D. W. (2005). The invasive and saprophytic syndromes due to <i>Aspergillus</i> spp.. MEDICAL MYCOLOGY, 43, S207-S238. doi:10.1080/13693780400025179

DOI
10.1080/13693780400025179
Journal article

2004

Molecular mechanisms of primary resistance to flucytosine in <i>Candida albicans</i>

Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004). Molecular mechanisms of primary resistance to flucytosine in <i>Candida albicans</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 48(11), 4377-4386. doi:10.1128/AAC.48.11.4377-4386.2004

DOI
10.1128/AAC.48.11.4377-4386.2004
Journal article

Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens

Hope, W. W., Padwell, A., Guiver, M., & Denning, D. W. (2004). Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. JOURNAL OF INFECTION, 49(2), 136-140. doi:10.1016/j.jinf.2004.02.008

DOI
10.1016/j.jinf.2004.02.008
Journal article

Optimising antifungal therapy for individual patients

Hope, W. W., & Denning, D. W. (2004). Optimising antifungal therapy for individual patients. INTERNAL MEDICINE JOURNAL, 34(4), 147-149. doi:10.1111/j.1444-0903.2004.00569.x

DOI
10.1111/j.1444-0903.2004.00569.x
Journal article

A PCR method for the identification of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) from screening swabs

Hope, W. W., Morton, A. P., Looke, D. F. M., Schooneveldt, J. M., & Nimmo, G. R. (2004). A PCR method for the identification of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) from screening swabs. PATHOLOGY, 36(3), 265-268. doi:10.1080/00313020410001692530

DOI
10.1080/00313020410001692530
Journal article

Invasive aspergillosis: current and future challenges in diagnosis and therapy

Hope, W. W., & Denning, D. W. (2004). Invasive aspergillosis: current and future challenges in diagnosis and therapy. CLINICAL MICROBIOLOGY AND INFECTION, 10(1), 2-4. doi:10.1111/j.1469-0691.2004.00809.x

DOI
10.1111/j.1469-0691.2004.00809.x
Journal article

2003

Sequential infection with <i>Nocardia farcinica</i> and <i>Cryptococcus neoformans</i> var. <i>gattii</i> in an immunocompetent host

Hope, W., & Looke, D. (2003). Sequential infection with <i>Nocardia farcinica</i> and <i>Cryptococcus neoformans</i> var. <i>gattii</i> in an immunocompetent host. JOURNAL OF INFECTION, 47(3), 256-259. doi:10.1016/S0163-4453(03)00083-5

DOI
10.1016/S0163-4453(03)00083-5
Journal article

2002

A case of bacteremic pyelonephritis due to Pasteurella multocida subsp. multocida

Hope, W. W., Flohr, G., & Nimmo, G. R. (2002). A case of bacteremic pyelonephritis due to Pasteurella multocida subsp. multocida. Clinical Microbiology Newsletter, 24(18), 140-141. doi:10.1016/s0196-4399(02)80036-8

DOI
10.1016/s0196-4399(02)80036-8
Journal article

Urine D-arabinitol/L-arabinitol ratio in diagnosing <i>Candida</i> infection in patients with haematological malignancy and HIV infection

Eisen, D. P., Bartley, P. B., Hope, W., Sigmundsdottir, G., Pehrson, C., Larsson, L., & Christensson, B. (2002). Urine D-arabinitol/L-arabinitol ratio in diagnosing <i>Candida</i> infection in patients with haematological malignancy and HIV infection. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 42(1), 39-42. doi:10.1016/S0732-8893(01)00310-8

DOI
10.1016/S0732-8893(01)00310-8
Journal article

Increase in prevalence of nosocomial non-<i>Candida albicans</i> candidaemia and the association of <i>Candida krusei</i> with fluconazole use

Hope, W., Morton, A., & Eisen, D. P. (2002). Increase in prevalence of nosocomial non-<i>Candida albicans</i> candidaemia and the association of <i>Candida krusei</i> with fluconazole use. JOURNAL OF HOSPITAL INFECTION, 50(1), 56-65. doi:10.1053/jhin.2001.1131

DOI
10.1053/jhin.2001.1131
Journal article